Production (Stage)
Yubo International Biotech Limited
YBGJ
$0.0612
$0.015233.04%
OTC PK
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -104.87% | |||
| Gross Profit | -- | 104.87% | |||
| SG&A Expenses | 33.76% | -28.15% | |||
| Depreciation & Amortization | 5.19% | -14.52% | |||
| Other Operating Expenses | 38.69% | -65.10% | |||
| Total Operating Expenses | 32.38% | -43.17% | |||
| Operating Income | -32.38% | 43.17% | |||
| Income Before Tax | -32.42% | 43.18% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -32.42% | 43.18% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -49.84% | 57.21% | |||
| Net Income | -50.36% | 50.12% | |||
| EBIT | -32.38% | 43.17% | |||
| EBITDA | -36.09% | 45.77% | |||
| EPS Basic | -50.00% | 50.00% | |||
| Normalized Basic EPS | -69.23% | 55.17% | |||
| EPS Diluted | -50.00% | 50.00% | |||
| Normalized Diluted EPS | -69.23% | 55.17% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||